ReviewPharmacoEconomics2019

Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Matthew Walton et al.PubMed ↗Publisher ↗

No numbers read from the abstract.